Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis

References

• Kister I, Bacon TE, Chamot E, et al. Natural history of multiple sclerosis symptoms. Int J MS Care 2013;15:146-58
   PubMedGoogle Scholar
• Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the “5E” study. Expert Rev. Pharmacoecon Outcomes Res 2011;11(2):205-13
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, González-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci 2013;123(6):400-8
   PubMed Web of Science ®Google Scholar
• Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10(5):589-95
   PubMed Web of Science ®Google Scholar
• Bensmail D, Vermersch P. Epidemiology and clinical assessment of spasticity in multiple sclerosis [Article in French]. Rev Neurol (Paris) 2012;168(Suppl 3):S45-50
   PubMedGoogle Scholar
• Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis–clinical characteristics, treatment and quality of life. Acta Neurol Scand 2014;129(3):154-62
   PubMed Web of Science ®Google Scholar
• Vermersch P. MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study. Neurodegener Dis Manag 2014;4(6):407-15
   PubMedGoogle Scholar
• Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009;26(12):1043-57
   PubMed Web of Science ®Google Scholar
• Arroyo R, Massana M, Vila C. Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study. Int J Neurosci 2013;123(12):850-8
   PubMed Web of Science ®Google Scholar
• Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 2014;129(1):13-20
   PubMed Web of Science ®Google Scholar
• Zettl UK, Henze T, Essner U, Flachenecker P. Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I). Eur J Health Eco 2014;15(9):953-66
   PubMed Web of Science ®Google Scholar
• Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7(40):iii,ix-x,1-111
   Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003(4):CD001332
   Google Scholar
• Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10(4):434-41
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, et al. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32(5):451-9
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomised, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18(9):1122-31
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice–results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014;71(5-6):271-9
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Henze T, Zettl UK. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 2014;72(1-2):95-102
   PubMed Web of Science ®Google Scholar
• García-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 2013;13(3 Suppl 1):9-13
   PubMed Web of Science ®Google Scholar
• Eltayb A, Etges T, Wright S. An observational post approval registry study of patients prescribed Sativex®. Results from clinical practice. [Poster 34521]. Presented at 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2–5 October 2013; Copenhagen, Denmark
   Google Scholar
• Arroyo R, Vila C, Dechant KL. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res 2014;3:435-44
   PubMed Web of Science ®Google Scholar
• Sativex oromucosal spray. Summary of product characteristics. Almirall; Spain: 2010
   Google Scholar
• Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12(5):639-45
   PubMed Web of Science ®Google Scholar
• Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260:286-95
   Google Scholar
• Farrar JT, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30(5):974-85
   PubMed Web of Science ®Google Scholar
• Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010;16(11):1349-59
   PubMed Web of Science ®Google Scholar
• Slof J, Gras A. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model. Expert Rev Pharmacoecon Outcomes Res 2012;12(4):525-38
   Web of Science ®Google Scholar
• Slof J, Ruiz L, Vila C. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy. Expert Rev Pharmacoecon Outcomes Res 2015;15(3):1-13
   Google Scholar
• Lu L, Pearce H, Roome C, et al. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis. Pharmacoeconomics 2012;30(12):1157-71
   PubMed Web of Science ®Google Scholar
• Notcutt WG. A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine. Prim Health Care Res Dev 2013;14(2):192-9
   PubMed Web of Science ®Google Scholar
• Vachová M, Novotná A, Mares J, et al. A multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex® treatment on cognition and mood of patients with spasticity due to multiple sclerosis. J Mult Scler 2014;1:122
   Google Scholar
• Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997;126(5):376-80
   PubMed Web of Science ®Google Scholar